Planta Medica International Open 2017; 4(S 01): S1-S202
DOI: 10.1055/s-0037-1608466
Poster Session
Georg Thieme Verlag KG Stuttgart · New York

The safety and efficacy of Chinese formula Salviae Miltiorrhizae and Ligustrazine hydrochloride solution injection in the acute ischemic stroke patients

G Yan
1   Guizhou Baite Pharmaceutical Corporation, Guizhou, China
,
R Zhang
1   Guizhou Baite Pharmaceutical Corporation, Guizhou, China
,
W Zuo
1   Guizhou Baite Pharmaceutical Corporation, Guizhou, China
,
R Wang
1   Guizhou Baite Pharmaceutical Corporation, Guizhou, China
2   Zhejiang CONBA Pharmaceutical & Drug Research Development Corporation, Hangzhou, China
,
Y Ling
3   Medical Corporation Soujikai, Osaka, Japan
,
Y Kobayashi
4   Shimane University, Izumo, Japan
› Author Affiliations
Further Information

Publication History

Publication Date:
24 October 2017 (online)

 

Danshen ligustrazine formula (DL; salviae miltiorrhizae and ligustrazine hydrochloride solution) has been used in China for the treatment of acute ischemic stroke patients. In the present study, the safety and efficacy of DL injection for the treatment of patients with acute ischemic stroke were evaluated.

129 acute ischemic stroke patients and their National Institute of Health stroke scale (NIHSS) scores were less than 15 were randomly divided into trial group (n = 65) and the standard control group (n = 64). DL was applied by intravenous infusion, 10 ml/time, 1 times/day, with 5% glucose saline. As the standard control, citicoline sodium injection was applied intravenously, 0. 25 g/day, diluted with 5% glucose saline; Treatment was continued for 7 to 10 days and efficacy was evaluated at 7 days index score were scored. Symptomatic intracranial hemorrhage, severe systemic bleeding, or other serious adverse events associated with the drug application and death due to any cause of the first 24 hours within the symptoms of intracranial hemorrhage was recorded.

Final NIHSS score for DL treatment was from 4.61+2.00 to 1.85+2.33 and that for citicoline was from 4.71+2.32 to 1.84+1.77. There was no significant difference between the two groups in NIHSS score, Barthel index and Rankin score (P > 0.05). No obvious side effect was observed by DL treatment.

Effects on scores of acute ischemic stroke patients treated with DL was not significantly different from those treated. Efficacy indicators as the modified Rankin score (mRS), NIHSS, Barthel with citicoline. Safe, convenient and well tolerated in the treatment of patients with acute ischemic stroke by DL was evident.